Serum Mimecan Is Associated With Arterial Stiffness in Hypertensive Patients

BACKGROUND Mimecan plays an important role in endothelial and vascular smooth muscle cell integrity and may be involved the pathology of arterial stiffness. However, the role of mimecan in arterial stiffness in patients with hypertension is not well defined. METHODS AND RESULTS A total of 116 hypertension patients and 54 healthy controls were enrolled in the investigation. Hypertensive patients were divided into 2 groups: the with arterial stiffness group (brachial-ankle pulse wave velocity [baPWV] ≥1400 cm/s; n=83) and the without arterial stiffness group (baPWV <1400 cm/s; n=33). A noninvasive measure of vascular stiffness was performed using pulse wave velocity (PWV) measurement of baPWV. Hypertensive patients had higher baPWV, mimecan, and endothelin 1 (ET-1) than healthy controls. The arterial stiffness group had higher mimecan and endothelin 1 (ET-1) and lower ankle-brachial pressure index (ABI) than those without stiffness. In hypertensive patients, mimecan was inversely correlated with ABI (P<0.05) and positively correlated with baPWV, ET-1, and total cholesterol. On multivariable logistic regression analysis, diastolic blood pressure, mimecan, ET-1, and creatinine were independent predictors of arterial stiffness in hypertensive patients (P<0.05). CONCLUSIONS Mimecan levels are higher in hypertensive patients than in healthy controls. Increased plasma mimecan levels are independently associated with increased arterial stiffness as assessed by baPWV.